NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
POLYCILLIN-N (ampicillin sodium) by Bristol Myers Squibb is clinical pharmacology general immediately after completion of a 15-minute intravenous infusion of ampicillin and sulbactam, peak serum concentrations of ampicillin and sulbactam are attained. Approved for pneumonia, bacterial, hiv infections, lung abscess and 1 more indications.
Drug data last refreshed 2w ago
Mechanism of Action
CLINICAL PHARMACOLOGY General Immediately after completion of a 15-minute intravenous infusion of ampicillin and sulbactam, peak serum concentrations of ampicillin and sulbactam are attained. Ampicillin serum levels are similar to those produced by the administration of equivalent amounts of…
Worked on POLYCILLIN-N at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.